A Study to Compare the Pharmacokinetic Profiles of Etravil® Tablet 10mg and Etravil® Tablet 25mg

• Cmax of Amitryptiline in plasma [ Time Frame: Up to 72H ] [ Designated as safety issue: No ]
• AUClast of amityptyline in plasma [ Time Frame: UP to 72H ] [ Designated as safety issue: No ]

• Tmax of amityptyline in plasma [ Time Frame: Up to 72H ] [ Designated as safety issue: No ]
• terminal half-life (t1/2) of amityptyline in plasma [ Time Frame: Up to 72H ] [ Designated as safety issue: No ]
• CL/F of amityptyline in plasma [ Time Frame: Up to 72H ] [ Designated as safety issue: No ]

Randomized, Single dose, 2-way crossover, Open Study to compare the pharmacokinetics profile of Etravil®(Amitriptyline Hydrochloride) Tablet 10mg and Etravil®(Amitriptyline Hydrochloride) Tablet 25mg after a single oral administration in healthy male volunteers

• Drug: Etravil 10mg Tablet
  sigle dose
• Drug: Etravil 25mg Tablet
  single dose

• Experimental: Etravil 10
  Etravil 10mg given by oral administration intervention: drug: experimental Etravil 10mg
  Intervention: Drug: Etravil 10mg Tablet
• Experimental: Etravil 25
  Etravil 25mg given by orl administration intervention: drug: Experimental Etravil 25mg
  Intervention: Drug: Etravil 25mg Tablet

Inclusion Criteria:

• a healthy adult male within the range of 19 to 50 years old at the time of screening

• one with weight of more than 55kg, in the range of IBW 20%

  • IBW(kg)={height(cm)-100}*0.9
• one who understood completely about this study after the detailed explanation is given, decided to volunteer and gave written informed consent to participate in study in compliance with the requirement of the entire protocol.

Exclusion Criteria:

• one with clinically significant disease in liver, kidney, nerve system, respiratory system, endocrine system, blood, tumor, urinary system, cardiovascular system, mental disease or with medical history
• one with glaucoma
• one with disorders of micturition include benign prostatic hyperplasia
• one with gastrointestinal disease or with gastrointestinal surgical history which can affect the absorption of the investigational drug.
• one who is allergic or has clinically significant allergic history to tricyclic antidepressants(TCA)
• one who shows the following result in vital sign: hypotension(systolic pressure ≤ 100mmHg or diastolic pressure ≤ 65mmHg) or hypertension(systolic pressure ≥ 150mmHg or diastolic pressure ≥ 95mmHg)
• one who has drug abuse history
• one who has taken any prescribed drugs, herbal agents or crude drugs within 2 weeks before study drug administration, or who has taken any over-the-counter (OTC) drugs or vitamins (Investigators will determine his eligibility by considering the effect of the drug on his safety or pharmacokinetic results in case other inclusion/exclusion criteria is satisfied.)
• one who has participated in other clinical study within 2 months before study drug administration
• one who donated whole blood within 2 months or component blood within 1 month or who are donated within 1 month before the treatment
• one who drank Over 21 units/week of alcohol(1 unit = 10g of pure alcohol) or subjects who would not be able to stop drinking alcohol during the hospitalization
• one who are heavy smoker more than 10 cigarettes/day within 3 months prior to screening or subjects who would not be able to stop smoking during the hospitalization
• one who had a beverage containing caffeine, drank alcohol, or smoked within 48hrs before the hospitalization or who had a beverage containing grapefruits during the hospitalization
• one with clinically significant observations considered as unsuitable based on medical judgment by investigators